CHRISTOPHER R COGLE, MD
Osteopathic Medicine at Archer Rd, Gainesville, FL
License number
Florida ME76840
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
1600 SW Archer Rd, Gainesville, FL 32610
PO Box 918025, Orlando, FL 32891
PO Box 918025, Orlando, FL 32891
Phone
(352) 265-0062
(352) 265-0525 (Fax)
(352) 265-0525 (Fax)
Personal information
See more information about CHRISTOPHER R COGLE at radaris.comName
Address
Phone
10326 SW 21St Ave, Gainesville, FL 32607
510 NE 6Th Ave, Gainesville, FL 32601
1619 77Th Ter, Gainesville, FL 32607
206 7Th St, Gainesville, FL 32601
510 6Th St, Gainesville, FL 32601
Professional information
Associate Professor At The University Of Florida
Position:
Associate Professor of Medicine at University of Florida, Research Director, Shands Stem Cell Laboratory at University of Florida
Location:
Gainesville, Florida Area
Industry:
Medical Practice
Work:
University of Florida
since Jul 2004
-
Associate Professor of Medicine
University of Florida
since Jul 2004
-
Research Director, Shands Stem Cell Laboratory
University of Florida
Nov 2003 - Jun 2004
-
Post-Doctoral Associate
Education:
Duke University School of Medicine 2003 - 2003
Fellow, Blood & Marrow Transplantation University of Florida College of Medicine 2000 - 2003
Fellow, Medical Oncology University of Florida College of Medicine 1997 - 2000
Resident, Internal Medicine University of Florida College of Medicine 1993 - 1997
M.D., Medical School University of Florida 1990 - 1994
B.S., Medical Sciences
Fellow, Blood & Marrow Transplantation University of Florida College of Medicine 2000 - 2003
Fellow, Medical Oncology University of Florida College of Medicine 1997 - 2000
Resident, Internal Medicine University of Florida College of Medicine 1993 - 1997
M.D., Medical School University of Florida 1990 - 1994
B.S., Medical Sciences
Christopher R Cogle, Gainesville FL
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Hemotology Oncology in the Davis Cancer Pavilion
2000 SW Archer Rd, Gainesville, FL 32608 Shands at AGH
1600 Sw Archer Rd, Gainesville, FL 32610 Bone Marrow Transplant At Shands UF
1515 SW Archer Rd, Gainesville, FL 32608
2000 SW Archer Rd, Gainesville, FL 32608 Shands at AGH
1600 Sw Archer Rd, Gainesville, FL 32610 Bone Marrow Transplant At Shands UF
1515 SW Archer Rd, Gainesville, FL 32608
Education:
University of Florida (1997) Medical Oncology
Dr. Christopher R Cogle - MD (Doctor of Medicine)
Hospitals:
University Florida Hema/Onc
1600 SW Archer Rd SUITE M401, Gainesville 32610
Shands Hospital at the University of Florida
1600 West Archer Rd, Gainesville 32608
University Florida Hema/Onc
1600 SW Archer Rd SUITE M401, Gainesville 32610
Shands Hospital at the University of Florida
1600 West Archer Rd, Gainesville 32608
1600 SW Archer Rd SUITE M401, Gainesville 32610
Shands Hospital at the University of Florida
1600 West Archer Rd, Gainesville 32608
University Florida Hema/Onc
1600 SW Archer Rd SUITE M401, Gainesville 32610
Shands Hospital at the University of Florida
1600 West Archer Rd, Gainesville 32608
Education:
Medical Schools
University of Florida
Graduated: 1997
University of Florida
Graduated: 1997
Christopher Ramin Cogle, Gainesville FL
Specialties:
Oncologist
Address:
1600 Sw Archer Rd, Gainesville, FL 32610
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Modulating Angiogenesis
US Patent:
2011028, Nov 17, 2011
Filed:
Jan 22, 2010
Appl. No.:
13/145877
Inventors:
Edward W. Scott - Gainesville FL, US
Christopher R. Cogle - Gainesville FL, US
Christopher R. Cogle - Gainesville FL, US
International Classification:
A61K 39/395, A61P 35/00, A61P 35/02, A61K 31/7105
US Classification:
4241331, 4241581, 514 44 A
Abstract:
Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.
Modulating Angiogenesis
US Patent:
2009029, Nov 26, 2009
Filed:
Jan 23, 2009
Appl. No.:
12/358891
Inventors:
Edward W. SCOTT - Gainesville FL, US
Christopher R. COGLE - Gainesville FL, US
Christopher R. COGLE - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
A61K 39/395, A61P 35/02, A61P 35/00
US Classification:
4241451, 4241581
Abstract:
Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.